Literature DB >> 32861269

Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies.

Sarah E Rutstein1, Dawn K Smith2, Shona Dalal3, Rachel C Baggaley3, Myron S Cohen4.   

Abstract

When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and persistence; however, this intervention is time-limited and the need for PrEP fluctuates as risk behaviours change. In this Viewpoint we examine the current guidelines and early programmatic outcomes after starting, stopping, and restarting PrEP, and we review the implications of PrEP in relation to HIV testing algorithms. Guidelines suggest to discontinue PrEP when a person is no longer at risk for HIV, but effectively implementing this strategy requires support tools to make the decision of stopping and restarting PrEP that considers the complex relationship between risk perceptions and risk behaviours. Safely discontinuing PrEP also requires greater understanding of the daily dosing duration that is needed to protect the person after their last HIV exposure. Additionally, clear strategies are needed to re-engage a person as their HIV exposure risk changes over time.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32861269      PMCID: PMC7541752          DOI: 10.1016/S2352-3018(20)30203-4

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  67 in total

1.  Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs.

Authors:  Constance Delaugerre; Guillemette Antoni; Nadia Mahjoub; Gilles Pialoux; Eric Cua; Armelle Pasquet; Nolwenn Hall; Cécile Tremblay; Laurent Cotte; Catherine Capitant; Marie-Laure Chaix; Laurence Meyer; Jean-Michel Molina
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

2.  Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Authors:  Elske Hoornenborg; Maria Prins; Roel C A Achterbergh; Lycke R Woittiez; Marion Cornelissen; Suzanne Jurriaans; Neeltje A Kootstra; Peter L Anderson; Peter Reiss; Henry J C de Vries; Jan M Prins; Godelieve J de Bree
Journal:  Lancet HIV       Date:  2017-09-14       Impact factor: 12.767

3.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

4.  Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States.

Authors:  Dawn K Smith; Sherri L Pals; Jeffrey H Herbst; Sanjyot Shinde; James W Carey
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

5.  High Rate of Discontinuation May Diminish PrEP Coverage Among Young Men Who Have Sex with Men.

Authors:  Ethan Morgan; Daniel T Ryan; Michael E Newcomb; Brian Mustanski
Journal:  AIDS Behav       Date:  2018-11

6.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

7.  Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.

Authors:  Puja Van Epps; Brigid M Wilson; Will Garner; Lauren A Beste; Marissa M Maier; Michael E Ohl
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-15       Impact factor: 3.731

8.  Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications.

Authors:  Ian W Holloway; Ryan Dougherty; Jennifer Gildner; Sean C Beougher; Craig Pulsipher; Jorge A Montoya; Aaron Plant; Arleen Leibowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.771

9.  Cohort profile: l'Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada.

Authors:  Zoë R Greenwald; Mathieu Maheu-Giroux; Jason Szabo; Judith Alexia B Robin; Michel Boissonnault; Vinh-Kim Nguyen; Réjean Thomas
Journal:  BMJ Open       Date:  2019-06-27       Impact factor: 2.692

10.  Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.

Authors:  Jennifer A Smith; Sarah-Jane Anderson; Kate L Harris; Jessica B McGillen; Edward Lee; Geoff P Garnett; Timothy B Hallett
Journal:  Lancet HIV       Date:  2016-07       Impact factor: 12.767

View more
  13 in total

1.  Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States.

Authors:  William C Goedel; Brooke G Rogers; Yu Li; Amy S Nunn; Rupa R Patel; Brandon D L Marshall; Leandro A Mena; Lori M Ward; J Benjamin Brock; Siena Napoleon; Alexandra Zanowick-Marr; Kate Curoe; Ashley Underwood; Catrell J Johnson; Khadijra R Lockwood; Philip A Chan
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

2.  Switching to Non-daily Pre-exposure Prophylaxis Among Gay and Bisexual Men in Australia: Implications for Improving Knowledge, Safety, and Uptake.

Authors:  Steven P Philpot; Dean Murphy; Curtis Chan; Bridget Haire; Doug Fraser; Andrew E Grulich; Benjamin R Bavinton
Journal:  Sex Res Social Policy       Date:  2022-06-17

3.  PrEP user profiles, dynamics of PrEP use and follow-up: a cohort analysis at a Belgian HIV centre (2017-2020).

Authors:  Anke Rotsaert; Thijs Reyniers; Bart K M Jacobs; Thibaut Vanbaelen; Christophe Burm; Chris Kenyon; Bea Vuylsteke; Eric Florence
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

Review 4.  Delayed presentation of HIV among older individuals: a growing problem.

Authors:  Amy C Justice; Matthew B Goetz; Cameron N Stewart; Brenna C Hogan; Elizabeth Humes; Paula M Luz; Jessica L Castilho; Denis Nash; Ellen Brazier; Beverly Musick; Constantin Yiannoutsos; Karen Malateste; Antoine Jaquet; Morna Cornell; Tinei Shamu; Reena Rajasuriar; Awachana Jiamsakul; Keri N Althoff
Journal:  Lancet HIV       Date:  2022-02-23       Impact factor: 16.070

5.  Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis.

Authors:  Jing Zhang; Chunyan Li; Junjie Xu; Zhili Hu; Sarah E Rutstein; Joseph D Tucker; Jason J Ong; Yongjun Jiang; Wenqing Geng; Sarah T Wright; Myron S Cohen; Hong Shang; Weiming Tang
Journal:  Lancet HIV       Date:  2022-04       Impact factor: 16.070

6.  Non-selective distribution of infectious disease prevention may outperform risk-based targeting.

Authors:  Benjamin Steinegger; Iacopo Iacopini; Andreia Sofia Teixeira; Alberto Bracci; Pau Casanova-Ferrer; Alberto Antonioni; Eugenio Valdano
Journal:  Nat Commun       Date:  2022-05-31       Impact factor: 17.694

7.  Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency.

Authors:  Gideon Wolf; Nevil J Singh
Journal:  Viral Immunol       Date:  2021-02-17       Impact factor: 2.175

8.  Longitudinal trends in PrEP familiarity, attitudes, use and discontinuation among a national probability sample of gay and bisexual men, 2016-2018.

Authors:  Ian W Holloway; Evan A Krueger; Ilan H Meyer; Marguerita Lightfoot; David M Frost; Phillip L Hammack
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

9.  Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System.

Authors:  J Carlo Hojilla; Leo B Hurley; Julia L Marcus; Michael J Silverberg; Jacek Skarbinski; Derek D Satre; Jonathan E Volk
Journal:  JAMA Netw Open       Date:  2021-08-02

Review 10.  Roll-out of HIV pre-exposure prophylaxis: a gateway to mental health promotion.

Authors:  Daniel J Ikeda; Khameer Kidia; Bruce D Agins; Jessica E Haberer; Alexander C Tsai
Journal:  BMJ Glob Health       Date:  2021-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.